… Adipose tissue secretes many biologically active substances (… is composed of epicardial fat
(the epicardial adipose tissue (EAT) … Furthermore, EAT and pericardial fat volume are strongly …

… effect of dapagliflozin on EAT volume and P-wave indices. … into dapagliflozin group (n=18)
and conventional treatment group … the effects of dapagliflozin on EAT volume, measured using …

… Limited evidence suggests that SGLT-2i treatment can reduce EAT volume [11]. … treatment
with the SGLT-2i dapagliflozin, compared to placebo, has an impact on adipose tissue in …

… does not reflect all subepicardial adipose tissue volume, but that measurement value highly
… In conclusion, the present study suggests that treatment with dapagliflozin can reduce EAT …

… Dapagliflozin OR Canagliflozin OR SGLT2 inhibitor” AND “epicardial fat tissue OR epicardial
adipose tissue … accurate measurement of epicardial and thoracic fat distances and volumes. …

… The amount of FFAs released from 100 mg of fat tissue, after dapagliflozin treatment for 6
h, was measured with a fluorimeter at an excitation wavelength of 540 nm and an emission …

… adipose tissue volumes at different levels (epicardial, abdominal at the 4th vertebrae), and
liver vibration controlled transient elastography (Fibroscan Echosens) to assess the degree of …

… act is the epicardial adipose tissue, achieving a 10-20% change with 24 weeks of treatment
in … this study was to evaluate the effect of dapagliflozin on EFV in patients with ACS assessed …

… Epicardial adipose tissue (EAT) is a pathogenic fat depot that … impact of SGLT-2 inhibitor
on EAT volume and AF predictors. … dapagliflozin group (DG) (n=20) and conventional therapy …

… adipose tissue volume. In addition, it has been reported that SGLT-2 inhibitors might reduce
the risk of cardiovascular event. Epicardial adipose tissue (EAT) … on the EAT volume remains …